Challenges for HIV Pre-Exposure Prophylaxis among Men Who Have Sex with Men in the United States

PLoS Medicine

Volumn 9, Issue 8, 2012, Pages

  Mansergh, Gordon ^a   Koblin, Beryl A ^b   Sullivan, Patrick S ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NEW YORK BLOOD CENTER   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CONDOM; DISEASE SURVEILLANCE; DRUG EFFICACY; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; MALE; MALE HOMOSEXUAL; PRE EXPOSURE PROPHYLAXIS; PREVALENCE; PROPHYLAXIS; SEXUAL TRANSMISSION; UNITED STATES;

COMMUNICATION; CONSUMER HEALTH INFORMATION; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; PREVENTIVE HEALTH SERVICES; UNITED STATES;

EID: 84865560414     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001286     Document Type: Article

References (17)

1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Eng J Med 363: 2587-2599.
2. Thigpen MC, Kebaabetswe PM, Smith DK, Segolodi TM, Soud FA, et al. (2011) Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study [abstract WELBC01]. IAS Conference on HIV Pathogenesis,Treatment, and Prevention; July 2011; Rome, Italy.
3. University of Washington, International Clinical Research Center (2011) Pivotal study finds that HIV medications are highly effective as prophylaxis against HIV infection in men and women in Africa [press release]. 13 July 2011. Available: http://depts.washington.edu/uwicrc/research/studies/files/PrEP_PressRelease-UW_13Jul2011.pdf. Accessed 1 March 2012.
4. Mansergh G, Koblin BA, Colfax GN, McKirnan DJ, Flores SA, et al. (2010) Preefficacy use and sharing of antiretroviral medications to prevent sexually-transmitted HIV infection among US men who have sex with men. J Acquir Immune Defic Syndr 55 (2): e14-e16.
5. Sullivan P, Liu A, Fuchs J, Irby R, Tarver R, et al. (2011) Awareness of and intention to use PrEP: a post-iPrEX survey of US MSM. National HIV Prevention Conference; August 2011; Atlanta.
6. Koblin BA, Mansergh G, Frye V, Tieu HV, Hoover DR, et al. (2011) Condom use decision making in the context of hypothetical pre-exposure prophylaxis efficacy among substance-using men who have sex with men: Project MIX. J Acquir Immune Defic Syndr 58 (3): 319-327.
7. Buchbinder SP, Liu A, (2011) Pre-exposure prophylaxis and the promise of combination prevention approaches. AIDS Behav Supp 1: S72-S79.
8. Myers GM, Mayer KH, (2011) Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDs 25: 63-71.
9. Underhill K, Operario D, Mimiaga MJ, Skeer MR, Mayer KH, (2010) Implementation science of pre-exposure prophylaxis: preparing for public use. Curr HIV/AIDS Rep 7: 210-219.
10. Mayer K, Mimiaga M, White J, Krakower D Vanderwarker R (2011) Knowledge, attitudes, and beliefs of Massachusetts physicians regarding topical and oral antiretroviral chemoprophylaxis. Conference on Retroviral and Opportunistic Infections; February 2011; Boston. Session 195, abstract 1000.
11. Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH, (2009) Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr 50: 77-83.
12. US Centers for Disease Control and Prevention (2011) Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. Morbid Mortal Weekly Rep 60: 65-68 Available: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a1.htm?s_cid=mm6003a1_w. Accessed 1 March 2012.
13. Amico KR, (2011) Standard of care for antiretroviral therapy adherence and retention in care from the perspective of care providers attending the 5th International Conference on HIV Treatment Adherence. J Int Assoc Physicians AIDS Care (Chic) 10 (5): 291-296.
14. Abbas UL, Hood G, Wetzel AW, Mellors JW, (2011) Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP). PLoS ONE 6 (4): e18165 doi:10.1371/journal.pone.0018165.
15. Supervie V, Barrett M, Kahn JS, Musaka G, Moeti TL, et al. (2011) Modeling dynamic interactions between PrEP interventions and treatment programs: predicting HIV transmission and resistance. Sci Rep 1: 185.
16. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, et al. (2009) HIV preexposure prophylaxis in the United States: Impact on lifetime infection risk, clinical outcomes, and cost effectiveness. Clin Infect Dis 48: 806-815.
17. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Eng J Med 365 (6): 493-505.